Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Capecitabine Rtd

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Early P 1 (1)
P 1 (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06756295Early Phase 1Not Yet RecruitingPrimary

A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

NCT01493336Phase 1CompletedPrimary

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Showing all 2 trials

Research Network

Common Treatments

  • Capecitabine Rtd1
  • Individualized Tumor Fast Vaccine Combination Including Adjuvant1
  • Capecitabine Xeloda1

Active Sponsors

  • Hoffmannla Roche1
  • Fengming Kong1
  • Peking University1
  • The University Of Hong Kongshenzhen Hospital1

Related Conditions

  • Melanoma1
  • Lung Cancer1

Activity Timeline